A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
5PSQ-035 Intensificating therapy with ustekinumab in non-first-line Crohn's disease: clinical experience, safety and effectiveness in the 'real world'
Section 5: Patient safety and quality assurance
Aim and objectives This study aimed to analyse the reliability of the CLEO scale. Material and methods From the 171 modelled clinical situations in Pharmaclass, the 50 most frequent were chosen. For each situation a PI was retrospectively and randomly selected between November 2019 and November 2020 in the AVIC-ENNE database. It contained 1263 PI transmitted after of Pharmaclass alerts' analysis in two 1700 beds health facilities. A multiprofessional panel of 11 clinicians have rateddoi:10.1136/ejhpharm-2022-eahp.272 fatcat:cbakcmjds5bkvmi6uvu4klpojm